Insider Buying: TELA Bio, Inc. (NASDAQ:TELA) Insider Buys 7,002 Shares of Stock


Share on StockTwits

TELA Bio, Inc. (NASDAQ:TELA) insider Ew Healthcare Partners Fund 2, acquired 7,002 shares of TELA Bio stock in a transaction that occurred on Wednesday, January 13th. The shares were purchased at an average cost of $13.90 per share, for a total transaction of $97,327.80. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

  • On Thursday, February 4th, Ew Healthcare Partners Fund 2, acquired 2,822 shares of TELA Bio stock. The shares were purchased at an average cost of $14.29 per share, for a total transaction of $40,326.38.
  • On Monday, February 1st, Ew Healthcare Partners Fund 2, acquired 1,119 shares of TELA Bio stock. The shares were purchased at an average cost of $14.16 per share, for a total transaction of $15,845.04.
  • On Thursday, January 28th, Ew Healthcare Partners Fund 2, purchased 13,950 shares of TELA Bio stock. The stock was bought at an average cost of $13.68 per share, for a total transaction of $190,836.00.
  • On Tuesday, January 26th, Ew Healthcare Partners Fund 2, purchased 1,544 shares of TELA Bio stock. The stock was bought at an average cost of $14.24 per share, for a total transaction of $21,986.56.
  • On Friday, January 15th, Ew Healthcare Partners Fund 2, purchased 763 shares of TELA Bio stock. The stock was bought at an average cost of $13.88 per share, for a total transaction of $10,590.44.

Shares of NASDAQ TELA traded down $0.52 during midday trading on Tuesday, reaching $15.76. The company’s stock had a trading volume of 2,072 shares, compared to its average volume of 24,083. The company has a current ratio of 16.65, a quick ratio of 15.90 and a debt-to-equity ratio of 0.54. TELA Bio, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $23.55. The stock has a market capitalization of $227.45 million, a price-to-earnings ratio of -5.42 and a beta of 2.08. The stock has a 50 day simple moving average of $14.69 and a 200-day simple moving average of $15.33.

Separately, Piper Sandler lifted their price target on shares of TELA Bio from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, November 11th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. TELA Bio has a consensus rating of “Buy” and an average price target of $19.80.

Several hedge funds and other institutional investors have recently bought and sold shares of TELA. Armistice Capital LLC raised its holdings in shares of TELA Bio by 60.0% in the fourth quarter. Armistice Capital LLC now owns 256,000 shares of the company’s stock valued at $3,850,000 after purchasing an additional 96,000 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of TELA Bio in the third quarter valued at approximately $615,000. BlackRock Inc. raised its holdings in shares of TELA Bio by 10.7% in the third quarter. BlackRock Inc. now owns 293,718 shares of the company’s stock valued at $4,859,000 after purchasing an additional 28,405 shares during the last quarter. Rossmore Private Capital increased its holdings in TELA Bio by 244.8% during the fourth quarter. Rossmore Private Capital now owns 34,484 shares of the company’s stock worth $519,000 after buying an additional 24,484 shares during the last quarter. Finally, Pura Vida Investments LLC increased its holdings in TELA Bio by 7.2% during the fourth quarter. Pura Vida Investments LLC now owns 309,323 shares of the company’s stock worth $4,652,000 after buying an additional 20,718 shares during the last quarter. Institutional investors own 67.59% of the company’s stock.

TELA Bio Company Profile

TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Recommended Story: Why do commodities matter?

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.